New DA-001 hair loss treatment heads to Large-Scale trial

NCT ID NCT06648850

Not yet recruiting Disease control Sponsor: Applied Biology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a treatment called DA-001 can safely reduce hair shedding and promote regrowth in people with certain types of hair loss, including telogen effluvium and female or male pattern baldness. About 1,120 adults will apply the treatment as directed and be monitored for changes in hair shedding and hair count. The goal is to see if DA-001 helps control hair loss and improve hair density.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia telogen effluvium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENETIC ALOPECIA ANDROGENETIC ALOPECIA (AGA) FEMALE PATTERN HAIR LOSS FEMALE PATTERN HAIR LOSS, ANDROGENIC ALOPECIA MALE PATTERN BALDNESS TELOGEN EFFLUVIUM

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.